English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18076/20274 (89%)
造訪人次 : 5242067      線上人數 : 986
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/32594


    標題: Effect of Bronchodilator and Steroid Use on Heart Disease and Stroke Risks in a Bronchiectasis-Chronic Obstructive Pulmonary Disease Overlap Cohort: A Propensity Score Matching Study
    作者: Yeh, Jun-Jun(葉俊濬)
    Yang, Yu-Cih
    Hsu, Chung Y.
    Kao, Chia-Hung
    貢獻者: Chia Yi Christian Hosp, Dept Famiy Med, Ditmanson Med Fdn
    Chia Nan Univ Pharm & Sci, Dept Early Childhood Educ & Nursery
    China Med Univ, Coll Med
    China Med Univ Hosp, Management Off Hlth Data
    China Med Univ, Grad Inst Biomed Sci, Coll Med
    China Med Univ, Sch Med, Coll Med
    China Med Univ Hosp, Dept Nucl Med
    Asia Univ, Dept Bioinformat & Med Engn
    China Med Univ Hosp, Ctr Augmented Intelligence Healthcare
    關鍵字: heart disease
    stroke
    bronchiectasis-chronic obstructive pulmonary disease overlap syndrome
    bronchodilator
    steroid
    日期: 2019-11
    上傳時間: 2020-07-29 13:51:17 (UTC+8)
    出版者: FRONTIERS MEDIA SA
    摘要: Background: To determine the effects of bronchodilator, steroid, and anti-arrhythmia drug use on the risk of heart disease/stroke (HDS) in patients with bronchiectasis-chronic obstructive pulmonary disease overlap syndrome (BCOS). Methods: We retrospectively enrolled patients with BCOS (BCOS cohort, n = 1,493) and patients without bronchiectasis and chronic obstructive pulmonary disease (COPD) (non-BCOS cohort, n = 5,972). The cumulative incidence of HDS was analyzed through Cox proportional regression. We calculated adjusted hazard ratios (aHRs) and their 95% confidence intervals (CIs) for HDS after adjustments for sex, age, comorbidities, long-acting beta 2-agonist or long-acting muscarinic antagonist (LABAs/LAMAs) use, short-acting beta 2-agonist or short-acting muscarinic antagonist (SABAs/SAMAs) use, oral steroid (OSs) or inhaled corticosteroid steroid (ICSs) use, and anti-arrhythmia drugs use. Results: The aHR (95% CI) for HDS was 1.08 (0.28-4.06) for patients using LAMAs compared with those not using drugs. Regarding drug use days, the aHRs (95% CIs) were 32.2 (1.79-773.0), 1.85 (1.01-3.39), and 31.1 (3.25-297.80) for those with recent SABAs use, past ICSs use, and past anti-arrythmia drugs use, respectively. Regarding cumulative drug dose, the aHRs (95% CIs) were 2.12 (1.46-3.10), 3.48 (1.13-10.6), 3.19 (2.04-4.99), 28.1 (1.42-555.7), 2.09 (1.32-3.29), 2.28 (1.53-3.40), and 1.93 (1.36-2.74) for those with a low dose of SABAs, medium dose of SABAs, low dose of SAMAs, low dose of ICSs, medium dose of ICSs, low dose of OSs, and medium dose of OSs, respectively. Conclusions: Compared with patients without bronchiectasis and COPD, BCOS patients with recent SABAs, past ICSs, and past anti-arrhythmia drugs use; a low or medium SABAs ICSs, and OSs dose; and a low SAMAs dose had a higher risk of HDS. LAMAs were not associated with HDS.
    關聯: Frontiers in Pharmacology, v.10, 1409
    顯示於類別:[嬰幼兒保育系] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    10.3389-fphar.2019.01409.pdf923KbAdobe PDF471檢視/開啟
    index.html0KbHTML1226檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋